Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality rates, especially in vulnerable populations. CDI ...

Clostridioides difficile (C. difficile) infection (CDI) is a significant healthcare-associated infection, known for its high morbidity and mortality ...

Fzata, Inc. announces the execution of a clinical trial agreement with the National Institutes of Health (NIH) to sponsor a ...

People with recurrent infections are at higher risk of complications. The C. diff bacteria can produce toxins that irritate ...

Clostridium difficile infection (CDI ... with positive samples then confirmed using a toxin(s) test, to distinguish toxinogenic from nontoxinogenic CDI. Although metronidazole and vancomycin ...

Hypoxia-inducible factor (HIF) signaling protects the intestinal mucosa from injury induced by Clostridium difficile toxins, according to the results of a study published in Gastroenterology.

For patients with inflammatory bowel disease (IBD), risk factors associated with Clostridioides difficile infection (CDI) ...

difficile) infection ... while preliminary evidence suggests it may also inhibit the production of bacterial toxins. This dual action could be particularly valuable in addressing antibiotic ...

difficile treatment. Oral FZ002 is a live yeast genetically modified to express a tetraspecific anti-toxin for C. difficile in the gastrointestinal (GI) tract. FZ002 is a first-in-class multi ...